Myovant Sciences Ltd. MYOV
We take great care to ensure that the data presented and summarized in this overview for Myovant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MYOV
View all-
Act Capital Management, LLC Wayne, PA60KShares$01.49% of portfolio
-
Four Thought Financial, LLC Venice, FL1KShares$00.0% of portfolio
-
American Portfolios Advisors Holbrook, NY219Shares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,97Shares$00.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$00.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in MYOV
Top Purchases
Top Sells
About MYOV
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Insider Transactions at MYOV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2023
|
David C Marek Principal Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
417,599
-61.46%
|
-
|
|
Mar 10
2023
|
Uneek Mehra Principal Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
202,696
-55.11%
|
-
|
|
Mar 10
2023
|
Lauren Merendino Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
169,538
-56.43%
|
-
|
|
Mar 10
2023
|
Myrtle S Potter Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Nancy Valente Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
246,684
-67.55%
|
-
|
|
Mar 10
2023
|
Terrie Curran Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Mark Guinan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Adele M. Gulfo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,673
-100.0%
|
-
|
|
Mar 10
2023
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
354,303
-65.97%
|
-
|
|
Mar 10
2023
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
51,599,200
+52.98%
|
$1,393,178,400
$27.0 P/Share
|
|
Mar 03
2023
|
Sumitomo Chemical Co., Ltd. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,243,005
-8.48%
|
-
|
|
Jan 18
2023
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,008
-1.17%
|
$52,208
$26.89 P/Share
|
|
Jan 18
2023
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
1,272
-0.36%
|
$33,072
$26.89 P/Share
|
|
Jan 18
2023
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,109
-0.45%
|
$28,834
$26.89 P/Share
|
|
Jan 18
2023
|
David C Marek Principal Executive Officer |
SELL
Open market or private sale
|
Direct |
8,037
-1.89%
|
$208,962
$26.89 P/Share
|
|
Jan 04
2023
|
Matthew Lang General Counsel & Corp. Secy. |
SELL
Open market or private sale
|
Direct |
2,779
-0.78%
|
$72,254
$26.9 P/Share
|
|
Jan 04
2023
|
Ferreira Juan Camilo Arjona Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,251
-0.9%
|
$58,526
$26.9 P/Share
|
|
Dec 16
2022
|
Uneek Mehra Principal Financial Officer |
SELL
Open market or private sale
|
Direct |
2,241
-1.09%
|
$58,266
$26.75 P/Share
|
|
Oct 26
2022
|
Nancy Valente Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,859
+50.0%
|
-
|